GlassScriptPhysician profile
Ghayyath Sultan
NPI 1780913996
$4,639.62
in general payments reported to CMS, 2019-2025
29 companies · $721 in 2025
The $721 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $257 · 2021: $437 · 2022: $840 · 2023: $620 · 2024: $1,368 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,709.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $970.28 | 2020-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $589.93 | 2019-2025 | Veltassa |
| Travere Therapeutics, INC. | $428.87 | 2024-2025 | Filspari |
| Amgen INC. | $315.70 | 2019-2025 | Tavneos |
| Otsuka America Pharmaceutical, INC. | $258.03 | 2021-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $254.85 | 2020-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $232.55 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $218.32 | 2020-2022 | |
| Medtronic, INC. | $213.68 | 2023-2024 | Ellipsys Vascular Access System |
| Aurinia Pharma U.S., INC. | $195.97 | 2022-2024 | Lupkynis |
| Calliditas Therapeutics US INC. | $169.09 | 2023-2024 | Tarpeyo |
| Fresenius USA Marketing, INC. | $125.01 | 2022-2025 | Velphoro, Velphoro, Korsuva |
| Baxter Healthcare | $116.88 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $113.89 | 2020-2022 | |
| Akebia Therapeutics INC | $92.04 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $53.16 | 2022-2023 | Benlysta |
| Mallinckrodt Enterprises LLC | $30.90 | 2019 | |
| Novartis Pharmaceuticals Corporation | $30.72 | 2025 | |
| Ardelyx, INC. | $30.28 | 2023 | Ibsrela |
| Recor Medical INC | $27.70 | 2025 | Paradise Ultrasound Renal Denervation System |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.72 | 2025 | |
| Alnylam Pharmaceuticals INC. | $23.92 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.48 | 2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $22.51 | 2022 | |
| Scpharmaceuticals INC. | $17.57 | 2025 | |
| Shire North American Group INC | $17.01 | 2019 | |
| Horizon Therapeutics Plc | $14.99 | 2021 | |
| Shield Therapeutics INC | $13.77 | 2022 | |
| Tactile Systems Technology INC | $12.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghayyath Sultan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.